Literature DB >> 22561658

Selective pulmonary pulsatile perfusion with oxygenated blood during cardiopulmonary bypass attenuates lung tissue inflammation but does not affect circulating cytokine levels.

Francesco Santini1, Francesco Onorati, Mariassunta Telesca, Tiziano Menon, Paola Mazzi, Giorgio Berton, Giuseppe Faggian, Alessandro Mazzucco.   

Abstract

OBJECTIVE: Improved respiratory outcome has been shown after selective pulsatile pulmonary perfusion (sPPP) during cardiopulmonary bypass (CPB). No contemporary study has analysed the impact of sPPP on alveolar and systemic inflammatory response in humans.
METHODS: Sixty-four patients undergoing a coronary artery bypass graft (CABG) were randomized to sPPP or standard CPB (32 patients each). An alveolar-arterial oxygen gradient (A-aDO(2)) was measured preoperatively (T0), at ICU arrival (T1), 3 h postoperatively (T2) and postextubation (T3). The bronchoalveolar lavage (BAL) was collected at T0, T1 and T2. White blood cells (WBCs), neutrophils, mononucleates and lymphocytes in BAL infiltrates were compared between the two groups. A cytokine assay for interleukin-1 (IL-1), IL-8, tumour necrosis factor alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1), growth regulated oncogene-alpha (GRO-α) and interferon (IFN)-γ was collected from the BAL and peripheral blood at the same time-points. Repeated-measure analysis of variance and non-parametric statistics were used to assess the between-group and during time differences.
RESULTS: The two groups proved comparable for perioperative variables. A-aDO(2) proved better after sPPP (group-P = 0.0001; group time-P < 0.0001). BAL infiltrates after sPPP showed lower WBCs, neutrophils and lymphocytes (group-P = 0.0001, group time-P = 0.0001 for all) together with higher mononucleates (group-P = 0.0001, group time-P = 0.0001). Proinflammatory cytokines and chemokine MCP-1 were lower in BAL after sPPP (group-P = 0.005, 0.034, 0.036 and 0.005, and group time-P = 0.001, 0.009, 0.001 and 0.0001 for IL-1, IL-8, TNF-α and MCP-1, respectively), whereas the immune modulator IFN-γ significantly augmented after sPPP (time-P = 0.0001) but remained stable after the standard CPB (time-P = 0.101, group-P = 001, group time-P = 0.0001). Indeed, serum cytokines were not different in the two groups during the study (P = NS at single time-points and as a function of time).
CONCLUSIONS: sPPP attenuates alveolar inflammation, as demonstrated by the lower neutrophilic/lymphocytic alveolar infiltration, and the secretion of anti-inflammatory rather than proinflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561658     DOI: 10.1093/ejcts/ezs199

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Pulmonary artery perfusion with anti-tumor necrosis factor alpha antibody reduces cardiopulmonary bypass-induced inflammatory lung injury in a rabbit model.

Authors:  Yang Yu; Mingxin Gao; Haitao Li; Fan Zhang; Chengxiong Gu
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

2.  Lung Protection Strategies during Cardiopulmonary Bypass Affect the Composition of Blood Electrolytes and Metabolites-A Randomized Controlled Trial.

Authors:  Katrine B Buggeskov; Raluca G Maltesen; Bodil S Rasmussen; Munsoor A Hanifa; Morten A V Lund; Reinhard Wimmer; Hanne B Ravn
Journal:  J Clin Med       Date:  2018-11-21       Impact factor: 4.241

Review 3.  Pulmonary artery perfusion versus no perfusion during cardiopulmonary bypass for open heart surgery in adults.

Authors:  Katrine B Buggeskov; Lars Grønlykke; Emilie C Risom; Mao Ling Wei; Jørn Wetterslev
Journal:  Cochrane Database Syst Rev       Date:  2018-02-08

4.  Dysfunction of alveolar macrophages after cardiac surgery and postoperative pneumonia?--An observational study.

Authors:  Katharina Chalk; Christian Meisel; Claudia Spies; Thomas Volk; Karin Thuenemann; Jörg Linneweber; Klaus-Dieter Wernecke; Michael Sander
Journal:  Crit Care       Date:  2013-12-09       Impact factor: 9.097

5.  Pulmonary artery perfusion versus no pulmonary perfusion during cardiopulmonary bypass in patients with COPD: a randomised clinical trial.

Authors:  Katrine B Buggeskov; Martin M Sundskard; Thomas Jonassen; Lars W Andersen; Niels H Secher; Hanne B Ravn; Daniel A Steinbrüchel; Janus C Jakobsen; Jørn Wetterslev
Journal:  BMJ Open Respir Res       Date:  2016-09-06

Review 6.  Pulmonary Protection Strategies in Cardiac Surgery: Are We Making Any Progress?

Authors:  Emad Al Jaaly; Mustafa Zakkar; Francesca Fiorentino; Gianni D Angelini
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

7.  Pulmonary Perfusion and Ventilation during Cardiopulmonary Bypass Are Not Associated with Improved Postoperative Outcomes after Cardiac Surgery.

Authors:  Yiliam F Rodriguez-Blanco; Angela Gologorsky; Tomas Antonio Salerno; Kaming Lo; Edward Gologorsky
Journal:  Front Cardiovasc Med       Date:  2016-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.